Adaptive Biotechnologies (ADPT) officer Lo sells 30,593 shares under 10b5-1 plan

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an open-market sale of 30,593 shares of common stock at a weighted average price of $14.08 per share on March 11, 2026. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance. Following the sale, Lo directly holds 291,374 shares of Adaptive Biotechnologies common stock and has an additional 2,500 shares held indirectly through a spouse. The sale price range for the trades was between $13.81 and $14.38 per share.

Insider Trade Summary 10b5-1

Net Seller: 30,593 shares ($430,749)

Net Sell 2 txns

Insider LO FRANCIS

Role Chief People Officer

Sold 30,593 shs ($431K)

Type	Security	Shares	Price	Value
Sale	Common Stock	30,593	$14.08	$431K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 291,374 shares (Direct); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LO FRANCIS

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		S(1)		30,593	D	$14.08(2)	291,374	D
Common Stock								2,500	I	By You Jin Lee (spouse)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Adaptive Biotechnologies (ADPT) report for Francis Lo?

Adaptive Biotechnologies reported that Chief People Officer Francis Lo sold 30,593 shares of common stock. The open-market sale occurred on March 11, 2026, at a weighted average price of $14.08 per share, under a pre-arranged Rule 10b5-1 trading plan.

At what prices were the Adaptive Biotechnologies (ADPT) shares sold by Francis Lo?

The filing lists a weighted average sale price of $14.08 per share. Individual trades occurred in multiple transactions at prices ranging from $13.81 to $14.38, and the company notes it can provide detailed breakdowns of shares sold at each price upon request.

How many Adaptive Biotechnologies (ADPT) shares does Francis Lo hold after the reported sale?

After the March 11, 2026 sale, Francis Lo directly owns 291,374 Adaptive Biotechnologies common shares. The filing also discloses an additional 2,500 shares held indirectly through his spouse, reflecting both direct and indirect ownership positions following the transaction.

Was the Adaptive Biotechnologies (ADPT) insider sale by Francis Lo under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed pursuant to a Rule 10b5-1 trading plan. This plan was adopted by Francis Lo on September 15, 2025, indicating the sales were pre-scheduled rather than timed opportunistically around short-term market movements.

What role does Francis Lo hold at Adaptive Biotechnologies (ADPT) in this Form 4 filing?

In the Form 4, Francis Lo is identified as an officer of Adaptive Biotechnologies, serving as Chief People Officer. The reported transaction therefore reflects trading activity by a senior executive, whose holdings and trades are subject to public disclosure under SEC rules.

Does the Form 4 show any derivative security exercises for Adaptive Biotechnologies (ADPT)?

No derivative security exercises are shown in this Form 4. The transaction summary indicates zero exercises and no derivative positions remaining in the derivative section, with the only reported trade being a common stock open-market sale of 30,593 shares by Francis Lo.